Minutes of the 19th Annual General Meeting of the Shareholders of MOLECULAR PARTNERS AG, held at 9:00 a.m. on 17 April 2024 at JED Events, Zürcherstrasse 39,.
25.08.2022 - Continued development of MP0317, with initial clinical data from Phase 1 study expected in the second half of 2022Initiation of Phase 1 study for MP0533 expected by year endContinued progression of proprietary DARPin-conjugated radioligand .
Research & Development Highlights: In January of 2022, announced positive topline results from Phase 2 EMPATHY clinical trial of ensovibep for the.